摘要
目的探究人表皮生长因子受体2低表达状态(Her-2-Low)在局限高危和寡转移性前列腺腺癌中的表达特点,为Her-2抗体耦联药物的应用提供数据支持。方法分析2021年8月至2023年4月解放军总医院泌尿外科行机器人辅助前列腺根治性切除术的患者共计100例,根据术前内分泌治疗与否分为内分泌治疗组(17例)和未内分泌治疗组(83例),根据转移状态分为局限高危组(71例)和寡转移组(29例),对其Her-2免疫组织化学染色结果进行统计学分析,采用秩和检验比较计量资料差异,表达率的差异比较采用卡方检验。结果Her-2-Low在局限高危和寡转移性前列腺腺癌中表达率约为59%,并未发现免疫组织化学3+结果;Her-2-Low的表达率上,内分泌治疗组显著高于未内分泌治疗组[82.4%(14/17)比54.2%(45/83),χ^(2)=4.618,P<0.05]。寡转移组显著高于局限高危组[75.9%(22/29)比52.1%(37/71),χ^(2)=4.801,P<0.05]。结论Her-2-Low在局限高危和寡转移性前列腺腺癌有较高的表达率,在术前接受内分泌治疗的高危和寡转移患者中可能存在更多Her-2抗体耦联药物敏感患者。
Objective The aim of this study was to investigate the expression characteristics of human epidermal growth factor receptor 2-Low(Her-2-Low)in limited high-risk and oligometastatic prostate adenocarcinomas.The findings will provide data to support the application of Her-2-targeted agents.Methods A total of 100 patients who underwent robotic-assisted radical prostatectomy at the Department of Urology,People’s Liberation Army(PLA)General Hospital from August 2021 to April 2023 were retrospectively analysed and divided into the Androgen Deprivation Therapy(ADT)group(n=17)and non-ADT group(n=83)according to preoperative treatment or not,and into the localized high-risk group(n=71)and the oligometastatic group(n=29)according to metastatic status.The results of their Her-2 immunohistochemical staining were statistically analysed,Differences in measures were compared using the rank sum test,and differences in expression rates were compared using the chi-square test.Results Her-2-Low was expressed in approximately 59%of localized high-risk and oligometastatic prostate adenocarcinomas and no immunohistochemical 3+results were found;The rate of Her-2-Low expression was significantly higher in the ADT-treated group compared to the non-ADT-treated group[82.4%(14/17)vs.54.2%(45/83),χ^(2)=4.618,P<0.05].Additionally,the oligometastatic group had a significantly higher rate of expression compared to the limited high-risk group[75.9%(22/29)vs.52.1%(37/71),χ^(2)=4.801,P<0.05].Conclusion Her-2-Low has a high expression rate in localized high-risk and oligometastatic prostate adenocarcinoma.There may be a higher proportion of trastuzumab-deruxtecan-sensitive patients in the group of patients with preoperative endocrine therapy and oligometastases.
作者
陈志强
高宇
杜松良
牛少曦
江彬
贾通宇
王保军
张旭
Chen Zhiqiang;Gao Yu;Du Songliang;Niu Shaoxi;Jiang Bin;Jia Tongyu;Wang Baojun;Zhang Xu(Department of Urology,the Third Medical Centre,Chinese People’s Liberation Army General Hospital,Beijing 100039,China)
出处
《中华实验外科杂志》
CAS
2024年第4期836-839,共4页
Chinese Journal of Experimental Surgery
基金
保健课题(21BJZ27)。
关键词
前列腺腺癌
人表皮生长因子受体2低表达状态
高危前列腺癌
寡转移
Prostate adenocarcinoma
Human epidermal growth factor receptor 2-Low
High-risk prostate cancer
Oligometastatic
